CTLPLawsuits•globenewswire•
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Sentiment:Negative (20)
Summary
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 25, 2025 by globenewswire